Evidence map›Paper›PMID 41089463›Full record

ArticleTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2025

IgG-Fc Glycosylation and a Novel Flowcytometric Assay to Predict Hemolytic Disease of the Fetus and Newborn.

Derek P de Winter, Thijs L J van Osch, Remco Visser, Tessa Vreeswijk, Zoltán Szittner, Peter C Ligthart, Julie van Coillie, Wenjun Wang, Jan Nouta, Anna M Wasynczuk and 6 more

Abstract read
In one paragraph

Article in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. "Baby You're Just Not Right for Me": The Various Problems of Feto-Maternal Incompatibilities.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Derek P de WinterDepartment of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, The Netherlands.
Thijs L J van OschDepartment of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, The Netherlands.
Remco VisserImmunoglobulin Research Laboratory, Department of Experimental Immunohematology, Sanquin Research, Amsterdam, The Netherlands.
Tessa VreeswijkDepartment of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, The Netherlands.
Zoltán SzittnerImmunoglobulin Research Laboratory, Department of Experimental Immunohematology, Sanquin Research, Amsterdam, The Netherlands.
Peter C LigthartDepartment of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, The Netherlands.
Julie van CoillieDepartment of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Wenjun WangCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Jan NoutaCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Anna M WasynczukCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Rick KapurDepartment of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, The Netherlands.
Manfred WuhrerCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
E J T VerweijDivision of Foetal Medicine, Department of Obstetrics, Leiden University Medical Center, Leiden, The Netherlands.
C Ellen van der SchootDepartment of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Masja de HaasDepartment of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, The Netherlands.
Gestur VidarssonImmunoglobulin Research Laboratory, Department of Experimental Immunohematology, Sanquin Research, Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Timely and accurate referral of pregnancies with red blood cell alloantibodies is essential to prevent perinatal death or long-term adverse consequences in hemolytic disease of the fetus and newborn (HDFN). Classically, antibody titers are used to select high-risk pregnancies. Research suggested that also IgG-Fc fucosylation could be an important pathological feature. We evaluated the diagnostic potential of IgG-Fc fucosylation in identifying high-risk pregnancies, and we report on a flowcytometric assay that integrates antibody quantity, antibody subclass and fetal FcγRIIIa affinity. Methods: Maternal serum samples from a nationwide prospective cohort of D-alloimmunized pregnancies, between 2014 and 2017, were used to evaluate IgG-Fc glycosylation in mass spectrometry ( Results: The cohort for mass-spectrometry analysis consisted of 31 pregnancies without transfusions (48%), 16 with intrauterine transfusion (IUT) (25%), and 17 (27%) with postnatal transfusions only. The flowcytometric assay consisted of 53 (59%) pregnancies without transfusions, 17 (19%) pregnancies with IUT, and 20 (22%) pregnancies with postnatal transfusions only, suggesting that severe HDFN was overrepresented. Anti-D IgG1 and IgG3-Fc-fucosylation levels were lower in groups requiring transfusions, but no distinct difference between groups was detected. No significant difference in other glycan traits was found. Among sera from 90 D-alloimmunized pregnancies evaluated in the flowcytometric assay, we found significant differences in IgG and FcγRIIIa bindings between pregnancies without transfusions and with IUT, suggesting a potential predictive value for the need for IUTs. ROC analyses revealed a lower false-positive rate at a 100% sensitivity in the prediction of pregnancies at risk for fetal anemia through the flowcytometric assay (20.8% for IgG binding and 43.1% for FcγRIIIa binding) compared to the titer and ADCC (74.6%). Conclusion: Anti-D IgG-Fc-fucosylation levels tended to be lower in pregnancies with IUT but could not distinguish pregnancies with or without IUT in this cohort. The flowcytometric assay, measuring IgG levels and functional FcγRIIIa binding, indicates that the specificity of serological monitoring in HDFN may be improved. Considering an overrepresentation of severe HDFN in this cohort, we advise to confirm these findings in a prospective cohort within a routine setting.

Indexed as

Exchange transfusionFetal anemiaHemolytic disease of the fetus and newbornIgG-Fc glycosylationIntrauterine transfusion

Identifiers

PMID41089463
PMCPMC12517675

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.